- Home
- GNTA vs MNPR Comparison
GNTA vs MNPR Comparison
Compare GNTA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | MNPR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 531.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNTA | MNPR |
|---|---|---|
| Price | $1.43 | $75.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $97.83 |
| AVG Volume (30 Days) | 106.2K | ★ 163.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $21.00 |
| 52 Week High | $10.00 | $105.00 |
Technical Indicators
Market Signals| Indicator | GNTA | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 31.23 | 43.53 |
| Support Level | $1.80 | $73.63 |
| Resistance Level | $1.77 | $79.31 |
| Average True Range (ATR) | 0.19 | 5.90 |
| MACD | -0.01 | -0.83 |
| Stochastic Oscillator | 9.40 | 9.91 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.